BNP Paribas Financial Markets’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $985K | Buy |
71,921
+69,503
| +2,874% | +$952K | ﹤0.01% | 2210 |
|
2025
Q1 | $26.7K | Sell |
2,418
-2,383
| -50% | -$26.4K | ﹤0.01% | 3625 |
|
2024
Q4 | $51.1K | Sell |
4,801
-3,745
| -44% | -$39.9K | ﹤0.01% | 3572 |
|
2024
Q3 | $109K | Buy |
8,546
+5,890
| +222% | +$74.8K | ﹤0.01% | 2712 |
|
2024
Q2 | $44.6K | Sell |
2,656
-37,139
| -93% | -$623K | ﹤0.01% | 2796 |
|
2024
Q1 | $597K | Buy |
39,795
+16,799
| +73% | +$252K | ﹤0.01% | 2128 |
|
2023
Q4 | $345K | Buy |
22,996
+6,617
| +40% | +$99.3K | ﹤0.01% | 2308 |
|
2023
Q3 | $229K | Buy |
16,379
+11,277
| +221% | +$158K | ﹤0.01% | 2379 |
|
2023
Q2 | $52.8K | Buy |
5,102
+4,925
| +2,782% | +$51K | ﹤0.01% | 2833 |
|
2023
Q1 | $1.64K | Sell |
177
-1,104
| -86% | -$10.2K | ﹤0.01% | 3016 |
|
2022
Q4 | $11.4K | Sell |
1,281
-50
| -4% | -$443 | ﹤0.01% | 2938 |
|
2022
Q3 | $11.1K | Sell |
1,331
-6,249
| -82% | -$52K | ﹤0.01% | 3458 |
|
2022
Q2 | $62.1K | Buy |
7,580
+5,881
| +346% | +$48.2K | ﹤0.01% | 2869 |
|
2022
Q1 | $14.8K | Sell |
1,699
-2,794
| -62% | -$24.3K | ﹤0.01% | 3185 |
|
2021
Q4 | $42.7K | Buy |
4,493
+934
| +26% | +$8.88K | ﹤0.01% | 3122 |
|
2021
Q3 | $59.9K | Buy |
3,559
+2,785
| +360% | +$46.8K | ﹤0.01% | 2868 |
|
2021
Q2 | $11.8K | Sell |
774
-3,665
| -83% | -$56K | ﹤0.01% | 3084 |
|
2021
Q1 | $86.5K | Buy |
4,439
+657
| +17% | +$12.8K | ﹤0.01% | 2853 |
|
2020
Q4 | $68.2K | Sell |
3,782
-806
| -18% | -$14.5K | ﹤0.01% | 2759 |
|
2020
Q3 | $88.5K | Buy |
4,588
+3,521
| +330% | +$67.9K | ﹤0.01% | 2570 |
|
2020
Q2 | $27.9K | Sell |
1,067
-5,031
| -83% | -$131K | ﹤0.01% | 2637 |
|
2020
Q1 | $109K | Buy |
6,098
+3,605
| +145% | +$64.3K | ﹤0.01% | 2554 |
|
2019
Q4 | $83.2K | Sell |
2,493
-866
| -26% | -$28.9K | ﹤0.01% | 2711 |
|
2019
Q3 | $80K | Buy |
+3,359
| New | +$80K | ﹤0.01% | 2612 |
|